ClinicalTrials.gg
RecruitingNCT07126821Updated Aug 17, 2025

A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data

An observational study in Brain (Nervous System) Cancers, Brain Arterial Disease and Neuro-Degenerative Disease, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Xiangya Hospital of Central South University · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Neurologic Manifestations with a site in China — 11 open to participants now, 11 under way, none of them phase 3. Neurologic Manifestations · China.

Planned enrollment
Largest of 10
100,000 · median 231
Started
2025
with 3 others
Observational
10 of 24
5 open now
Primary completion
2030-12
later than 9 of 10 live
Registered
21st of 24
by date

Among the 24 studies in Neurologic Manifestations with a site in China, this one has the largest planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2025, is one of 10 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 21st registered.

Neurologic Manifestations

427 studies on the registry are indexed under Neurologic Manifestations; 80 are open to participants now.

Browse Neurologic Manifestations studies →

Open to participants now

11 of the 24 studies in Neurologic Manifestations with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 59 Neurologic Manifestations studies recruiting now, 31 (53%) set no upper age limit and 15 (25%) stop at 75 or younger; 15 take children under 18; 12 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Neurologic Manifestations with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to develop an innovative, comprehensive, and explainable AI vision-language foundation model (VLM) to advance the diagnosis and interpretation of brain diseases using multi-modal data. We will include patient demographics, medical imaging data (such as MRI, CT, and PET scans), histopathological data, genomic data when available, and other necessary laboratory examinations and tests to establish a screening and diagnostic model for brain diseases.

Read the detailed description

Secondary Objective: To establish a comprehensive diagnostic model with uncertainty quantification and automated report generation that covers all brain diseases based on clinical indicators.

Exploratory Objective: To include MRI scans from large-scale populations for model validation.

03

Conditions studied

  • Brain (Nervous System) Cancers
  • Brain Arterial Disease
  • Neuro-Degenerative Disease
  • Brain Tumors
  • Brain Diseases
  • Neurological di

Keywords

  • brain tumors
  • brain cancers
  • brain diseases
  • foundation model
  • diagnosis
  • prediction
  • neurological diseases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with brain disease or Non-disease condition

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with brain diseases:

  • Patients with brain tumors were diagnosed.
  • Patients with other brain diseases were correctly diagnosed.
  • The clinical case data of all patients were complete.

Non-brain disease population:

  • All patients have complete clinical case data, complete brain MRI, no history brain diseases, no brain surgery or other brain diseases that affect the diagnosis and observation of MR imaging.

Exclusion criteria

Exclusion Criteria:

  • Cases in which MRI were incomplete or with significant noise and artifacts.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100,000 participants (estimated)
Patient registry
No

Interventions

  • OtherNo Interventions

    No Interventions

06

What researchers measure

Primary outcomes

  1. Brain Disease Diagnostic performance

    This study will evaluate how accurately the AI model can identify and differentiate between: 1. Brain tumors including gliomas, glioneuronal tumors, and neuronal tumor, meningioma, germ cell tumors, embryonal tumors, tumors of the sellar region, pineal region tumors, mesenchymal, non-meningothelial tumors, choroid plexus tumors, hematolymphoid tumors, cranial and paraspinal nerve tumors, melanocytic tumors and brain metastases based on WHO CNS 5 classification; 2. Brain diseases apart from brain tumors such as brain arterial disease, neurodegenerative disorders, etc.; 3. Normal brain findings; The model's performance will be assessed using sensitivity, specificity, F1-score AUC-ROC. Diagnostic ability of AI model will be compared against with pathological diagnosis(if possible), final clinical diagnoses by neurologists or radiologists.

    Time frame: Perioperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2030, 67 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 17, 2025
StartActual
May 15, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07126821
Responsible party
Xuan Gong (Associate Consultant, Xiangya Hospital of Central South University) — Principal investigator
First posted
Aug 17, 2025
Start date
May 15, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Aug 17, 2025

Study contacts

Xuan Gong, PhD.
Contact
gong.xuan@csu.edu.cn
0086-731-8975-3037
Zhou Chen, PhD.
Contact
czad0412@163.com
0086-13687397913

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion